ATRT-26. The PI3k inhibitor Paxalisib combines with the novel HDAC1/3 inhibitor RG2833 to improve survival in mice bearing orthotopic xenografts of atypical teratoid/rhabdoid tumors

Tyler Findlay(Johns Hopkins University), Jeffrey Rubens(Johns Hopkins University), Charles G. Eberhart(The University of Texas MD Anderson Cancer Center), Eric H. Raabe(Johns Hopkins University), Kristen Malebranche(Johns Hopkins University)
Neuro-Oncology
June 1, 2022
Cited by 3


Related Papers